Consequently, we hypothesize that elevated sCD40L in the serum of CRC patients might suppress anti-tumor immunity, explaining why CRC patients in the lowest sCD40L tertile exhibited better RFS compared to those in the middle and highest tertiles. This evidence concerns the gene CD40LG and colorectal carcinoma.